Timothy Atkins > Goodwin > Philadelphia, United States > Lawyer Profile
Goodwin Offices
One Commerce Square
2005 Market St, 32nd floor
Philadelphia, Pennsylvania
19103
United States
- Firm Profile
- Go to...
Timothy Atkins
Position
Partner
Career
Timothy C. Atkins is a partner in the Life Sciences group at Goodwin. He joined the firm in 2023. Tim advises startups and venture capital-backed business as well as publicly traded, global companies in the pharmaceutical, biotechnology, and medical device sectors. His work includes acquisition, protection, commercialization, and disposition of intellectual property assets as well as acting as outside general counsel for startup and emerging growth companies in the life sciences handling common formation, counseling of founders, private financings, and mergers and acquisitions.
Tim has extensive experience with life science-focused licensing, collaboration, joint development, joint venture transactions, and asset acquisition and dispositions transactions and with the panoply of commercial transactions pursued by life sciences companies including sponsored research, contract, manufacturing, supply, distribution, and clinical trial agreements.
Education
JD 1997 Villanova University Charles Widger School of Law (magna cum laude); BA 1991 University of Notre Dame
Lawyer Rankings
United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
(Firms to watch)Goodwin‘s patent prosecution collective has been significantly bolstered with the arrivals of David Chen to Santa Monica in October 2023 from Ropes & Gray LLP and of Pittsburgh-based Alicia Palladino, Philadelphia’s Daniel Scolnick and Timothy Atkins from Troutman Pepper in February of the same year.
Lawyer Rankings
Top Tier Firm Rankings
- Finance > Financial services regulation
- Industry focus > Cannabis
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- M&A/corporate and commercial > M&A: middle-market ($500m-999m)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- Finance > Capital markets: debt offerings
- International trade > CFIUS
- M&A/corporate and commercial > Corporate governance
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Dispute resolution > E-discovery
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Intellectual property > Patents: litigation (full coverage)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade > Customs, export controls and economic sanctions
- Healthcare > Service providers
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Commercial lending
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Intellectual property > Patents: litigation (International Trade Commission)
- M&A/corporate and commercial > Shareholder activism